AmerisourceBergen (ABC) Earning Somewhat Favorable News Coverage, Accern Reports

News stories about AmerisourceBergen (NYSE:ABC) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AmerisourceBergen earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.4795216620645 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

Shares of AmerisourceBergen (NYSE ABC) traded up $0.60 during trading on Tuesday, hitting $92.50. The stock had a trading volume of 772,669 shares, compared to its average volume of 1,611,557. The company has a debt-to-equity ratio of 1.83, a quick ratio of 0.48 and a current ratio of 0.91. The firm has a market capitalization of $20,940.23, a P/E ratio of 48.54, a PEG ratio of 1.61 and a beta of 1.02. AmerisourceBergen has a 1-year low of $71.90 and a 1-year high of $106.27.

AmerisourceBergen (NYSE:ABC) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $1.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.20. The firm had revenue of $40.47 billion during the quarter, compared to the consensus estimate of $40.42 billion. AmerisourceBergen had a return on equity of 56.29% and a net margin of 0.27%. The firm’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.36 earnings per share. analysts forecast that AmerisourceBergen will post 6.29 EPS for the current year.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of AmerisourceBergen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Cowen raised shares of AmerisourceBergen from a “market perform” rating to an “outperform” rating in a research note on Tuesday, October 10th. Jefferies Group set a $85.00 price target on AmerisourceBergen and gave the stock a “hold” rating in a report on Sunday, October 29th. Goldman Sachs Group upgraded AmerisourceBergen from a “neutral” rating to a “buy” rating in a report on Friday, December 15th. Finally, Leerink Swann set a $105.00 price target on AmerisourceBergen and gave the stock a “buy” rating in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $98.39.

In other AmerisourceBergen news, SVP Lazarus Krikorian sold 16,427 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $84.86, for a total value of $1,393,995.22. Following the completion of the transaction, the senior vice president now owns 23,360 shares in the company, valued at $1,982,329.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dale Danilewitz sold 1,857 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $74.69, for a total value of $138,699.33. The disclosure for this sale can be found here. In the last quarter, insiders sold 193,334 shares of company stock valued at $17,270,252. 27.30% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “AmerisourceBergen (ABC) Earning Somewhat Favorable News Coverage, Accern Reports” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at

About AmerisourceBergen

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.

Insider Buying and Selling by Quarter for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with's FREE daily email newsletter.

Leave a Reply